Study Results Show Neteera Patient Monitoring System Successfully Alerted for 77% of Hospitalizations, Aiding Timely Intervention

LEWES, Del., Oct. 1, 2025 /PRNewswire/ — Neteera Technologies Ltd. today announced results from a clinical study demonstrating that its contactless monitoring system achieved 77% sensitivity in detecting impending hospitalizations among nursing facility residents, providing a warning of 4.99 days on average for clinical intervention.

The comprehensive, retrospective study, conducted in partnership with TapestryHealth across five nursing facilities over a four-month period, monitored 612 residents and analyzed 96 hospitalization events. The results provide healthcare facilities with clinical evidence that Neteera’s FDA-cleared vital sign monitoring sensor technology can provide early warnings that may help care teams reduce avoidable hospitalizations through timely intervention.

Key Clinical Results:

  • 77% sensitivity for all hospitalization events, with first alerts issued on average 4.99 days before admission
  • 89% sensitivity for definite respiratory and cardiac deteriorations with a 5.65-day lead time
  • 71% specificity in high-sensitivity configuration; 86% specificity in high-specificity configuration

“This clinical evidence validates that Neteera’s technology can help care teams identify at-risk patients earlier to reduce avoidable hospitalizations while improving patient care,” said Isaac Litman, CEO of Neteera. “Clinical teams equipped with early warning alerts can intervene proactively, transforming emergency responses into treat-in-place care.”

The Neteera System utilizes ambient sensor technology to detect micro-movements from cardiac and respiratory activity through clothing and bedding, eliminating the need for wearable devices, cameras, or direct patient contact. By continuously tracking heart rate and respiratory rate, the system uses proprietary, AI-powered algorithms to analyze deviations from each patient’s baseline and alert when these deviations exceed the threshold.

“Early identification of patient deterioration fundamentally changes care delivery from reactive to proactive,” said Dr. Hans Jenkins, Chief Medical Officer at TapestryHealth. “When clinical teams receive alerts five days before emergency hospitalization becomes necessary, they can initiate targeted treatments and often resolve underlying conditions without hospital admission.”

About the Study: The retrospective analysis was conducted from November 2024 to February 2025, led by Dr. Shai Shechter and Dr. Alex Kazakov from Neteera. All patient data were handled in compliance with applicable privacy regulations and relevant data use agreements. The full study methodology and statistical analysis are available for download.

About TapestryHealth: TapestryHealth delivers technology solutions supporting clinical care delivery and patient monitoring in healthcare facilities. Visit tapestryhealth.com.

About Neteera: Neteera develops contactless sensing solutions using proprietary micro-radar technology to deliver real-time patient insights in healthcare settings. The system continuously measures vital signs without the need for wearables, cameras, or microphones. Visit neteera.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/study-results-show-neteera-patient-monitoring-system-successfully-alerted-for-77-of-hospitalizations-aiding-timely-intervention-302567520.html

SOURCE Neteera

Staff

Recent Posts

Is SynergyRx GLP-1 Legitimate? Platform Lists Compounded Semaglutide at $200 With Oral Tablet Options

Telehealth Provider Offers FDA-Approved and Compounded Weight Loss Medications in All 50 States, Subject to…

14 hours ago

Direct Meds GLP-1 Medications Platform Maintains LegitScript Certification as New Year Weight Loss Interest Peaks Amid Compounding Regulatory Shifts

Telehealth Platform Facilitates Compounded Semaglutide and Tirzepatide Access Through Licensed Provider Evaluation as FDA Shortage…

14 hours ago

Best Peptides for Boosting Growth Hormone: ReadyRx Lists Prescription Sermorelin in Injectable and Needle-Free Formats for 2026

Analysis examines best peptides for boosting growth hormone as ReadyRx lists prescription sermorelin in injectable…

14 hours ago

Best Fat Burner For Men 2026: Effective Fat Burning Supplements For Men’s Belly Fat Launched By Wolfson Brands Ltd

Discover the best fat burner for men in 2025. Explore Wolfson Brand’s effective fat-burning supplements…

15 hours ago

MEDIROM Partners with World

Deploying “Proof of Human” Infrastructure throughout Japan, a Technology Envisioned by Sam Altman and Alex…

15 hours ago